Catalyst announces VISION-DMD vamorolone study published in Neurology

CATALYST PHARMACEUTICALS, INC.

Peer-reviewed journal Neurology published Santhera's VISION-DMD study on vamorolone (AGAMREE) for DMD.
Study of 121 boys aged 4 to <7 years showed 6 mg/kg/d vamorolone maintained motor improvements to 48 weeks.
Vamorolone reversed prednisone-induced bone morbidities including stunted growth and bone biomarker decline.
Catalyst holds exclusive North American commercialization rights for AGAMREE, already approved in US.
Results support long-term efficacy and safety profile of vamorolone for Duchenne muscular dystrophy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.